Biotronik has landed exclusive U.S. distributorship for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor.
MoMe Kardia was designed to increase early detection and diagnosis of cardiac arrhythmias by providing physicians with the ability to access near real-time electrocardiographic data. Monitoring can also uncover patients at higher risk of sudden cardiac death.
MoMe’s automated cloud-based analytics make patient data available to physicians without the need for costly third-party services, according to the Lowell, Mass.-based InfoBionic. Medication compliance can be identified and managed, symptoms can be correlated with rhythms, and triggers of cardiac events can be found by analyzing the onset and resolution data of an event.
“MoMe is unique in providing near real-time full disclosure electrocardiographic monitoring,” said Dr. Colin Movsowitz, a Philadelphia electrophysiologist, in a prepared statement from Biotronik. “It replicates a hospital telemetry monitoring center. MoMe allows clinical decisions to be made on data rather than assumptions. It sets a new standard in providing physicians easy access to ambulatory electrocardiographic data.”
Patients can be trained on how to use the one-button monitor. Once the patient is home, physicians can remotely switch the monitor between Holter, Event and Mobile Cardiac Telemetry — lessening the need for office visits and saving time and money for the patient. From enrollment to diagnosis, physicians have total control of the monitor.
“With MoMe we’ve extended our portfolio of cardiovascular solutions to support physicians in providing the best care possible as early as possible,” said Marlou Janssen, president of Biotronik. “MoMe provides access to critical data and workflow efficiencies that help physicians identify and prevent cardiac events. It is a critical step in providing comprehensive cardiac care.”
Biotronik (Berlin, Germany) manufactures a broad range of cardiac and vascular devices, along with a wide assortment of leads.
